Citations

Showing 10 of 108094 citations.

Calibration of concomitant field offsets using phase contrast MRI for asymmetric gradient coils
Abad, Nastaren , Lee, Seung‐Kyun , Ajala, Afis , In, Myung‐Ho , Frigo, Louis M., Morris, H Douglas , Hua, Yihe , Ho, Vincent B. , Bernstein, Matt A. , Foo, Thomas , Bernstein, Matt A , Foo, Thomas K F , In, Myung-Ho , Bhushan, Chitresh

Mayo Clinic

Magnetic Resonance in Medicine | September 21, 2022 | Volume: 89 | Issue: 1 | Pages: 262-275

10.1002/mrm.29452 | PMID 36129000 Get It

PurposeAsymmetric gradient coils introduce zeroth‐ and first‐order concomitant field terms, in addition to higher‐order terms common to both asymmetric and symmetric gradients. Salient to compensation strategies is the accurate calibration of the concomitant field spatial offset parameters for asymmetric coils. A method that allows for one‐time calibration of the offset parameters is described.Theory and MethodsA modified phase contrast pulse sequence with single‐sided bipolar flow encoding is proposed to calibrate the offsets for asymmetric, transverse gradient coils. By fitting the measured phase offsets to different gradient amplitudes, the spatial offsets were calculated by fitting the phase variation. This was used for calibrating real‐time pre‐emphasis compensation of the zeroth‐ and first‐order concomitant fields.ResultsImage quality improvement with the proposed corrections was demonstrated in phantom and healthy volunteers with non‐Cartesian and Cartesian trajectory acquisitions. Concomitant field compensation using the calibrated offsets resulted in a residual phase error <3% at the highest gradient amplitude and demonstrated substantial reduction of image blur and slice position/selection artifacts.ConclusionsThe proposed implementation provides an accurate method for calibrating spatial offsets that can be used for real‐time concomitant field compensation of zeroth and first‐order terms, substantially reducing artifacts without retrospective correction or sequence specific waveform modifications.
Glucocorticoids mediate transcriptome‐wide alternative polyadenylation: Potential mechanistic and clinical implications
Nguyen, Thanh Thanh L. , Liu, Duan , Gao, Huanyao , Ye, Zhenqing, Lee, Jeong‐Heon , Yu, Jia , Zhang, Lingxin , Wang, Liewei , Ördög, Tamás , Weinshilboum, Richard M. , Wang, Liewei , Ordog, Tamas , Weinshilboum, Richard M. , Nguyen, Thanh Thanh L. , Lee, Jeong-Heon , Liu, Duan , Wei, Lixuan

Mayo Clinic

Clinical and Translational Science | September 21, 2022 | Volume: 15 | Issue: 11 | Pages: 2758-2771

10.1111/cts.13402 | PMID 36128656 Get It

AbstractAlternative polyadenylation (APA) is a common genetic regulatory mechanism that generates distinct 3′ ends for RNA transcripts. Changes in APA have been associated with multiple biological processes and disease phenotypes. However, the role of hormones and their drug analogs in APA remains largely unknown. In this study, we investigated transcriptome‐wide the impact of glucocorticoids on APA in 30 human B‐lymphoblastoid cell lines. We found that glucocorticoids could regulate APA for a subset of genes, possibly by changing the expression of 142 RNA‐binding proteins, some with known APA‐regulating properties. Interestingly, genes with glucocorticoid‐mediated APA were enriched in viral translation‐related pathways, while genes with glucocorticoid‐mediated expression were enriched in interferon and interleukin pathways, suggesting that glucocorticoid‐mediated APA might result in functional consequences distinct from gene expression. For example, glucocorticoids, a pharmacotherapy for severe COVID‐19, were found to change the APA but not the expression of LY6E, an important antiviral inhibitor in coronavirus diseases. Glucocorticoid‐mediated APA was also cell‐type‐specific, suggesting an action of glucocorticoids that may be unique to immune regulation. We also observed evidence for genotype‐dependent glucocorticoid‐mediated APA (referred to as pharmacogenomic‐alterative polyadenylation quantitative trait loci), providing potential functional mechanisms for a series of common genetic variants that had previously been associated with immune disorders, but without a clear mechanism. In summary, this study reports a series of observations regarding the impact of glucocorticoids on APA, raising the possibility that this mechanism might have implications for both disease pathophysiology and drug therapy.
Impact of intracardiac echocardiography on readmission morbidity and mortality following atrial fibrillation ablation
Deshpande, Saurabh , Sawatari, Hiroyuki , Ahmed, Raheel , Nair, Rakesh Gopinathan, Somers, Virend K., Chahal, C. Anwar A. , Padmanabhan, Deepak , Gopinathannair, Rakesh , Gopinathannair, Rakesh , Khan, Hassan , Padmanabhan, Deepak , Chahal, Choudhary Anwar A , Ahmed, Raheel , Deshpande, Saurabh , Khanji, Mohammed Y , Somers, Virend K.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 21, 2022 | Volume: 33 | Issue: 12 | Pages: 2496-2503

10.1111/jce.15683 | PMID 36128625 Get It

AbstractIntroductionThe use of intracardiac echocardiography (ICE) is beneficial during the ablation of atrial fibrillation (AF). Evidence is conflicting regarding the clinical impact of using ICE on arrhythmia recurrence and mortality.MethodsPatients undergoing catheter ablation of AF during 2010–2017 were identified using the International Classification of Diseases‐9th and 10th Revision‐Clinical Modification (ICD‐9‐CM and ICD‐10‐CM) from the Nationwide Readmissions Database. Propensity matching was used to generate a control group. Patient demographics, Charlson comorbidity indexes, time from discharge to readmission, and the reason of readmission were extracted.ResultsFrom 2010 to 2017, 51 129 patients were included in the analysis out of which ICE was used in 8005 (15.7%) patients. The in‐hospital mortality at readmission was significantly higher in the patients without ICE use (2.9% vs. 1.7%, p = .02). The length of stay (LOS) at readmission was significantly higher in non‐ICE arm (median [interquartile range, IQR]: 3 [2–6] vs. 2 [3–5] days, p < .0001) with similar healthcare‐associated cost (HAC) in both the groups (median [IQR]: US$7507.3 [4057.8–15 474.2] vs. 7339.4 [4024.8–15 191.6], p = .43). Freedom from readmission was 12% higher (hazard ratio [HR] [95% confidence interval, CI]: 0.88 [0.83–0.94], p < .0001) with the use of ICE at 90‐day follow‐up, which was driven by 24% reduction in heart failure (HF) at follow‐up (HR [95% CI]: 0.76 [0.60–0.96], p = .02).ConclusionsICE use during AF ablation procedure reduces readmissions at 90 days by 12%, driven by a 24% decrease in HF‐related admissions. The non‐ICE arm showed a significantly higher LOS which offsets marginally higher HAC in the ICE arm.
Validation of the Achalasia Patient‐Reported Outcomes Questionnaire
Pandolfino, John E. , Carlson, Dustin A. , McGarva, Josie, Kahrilas, Peter J. , Vaezi, Michael F. , Katzka, David A. , Taft, Tiffany , Katzka, D A , Taft, Tiffany H

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 21, 2022 | Volume: 56 | Issue: 10 | Pages: 1434-1443

10.1111/apt.17230 | PMID 36127750 Get It

SummaryBackgroundAchalasia is a debilitating major motor disorder of the oesophagus. Hypervigilance and symptom‐specific anxiety substantially impact dysphagia symptom reporting, and quality of life is a critical patient outcome. Earlier achalasia symptom scales did not consider these constructs in their psychometric development.AimTo develop a new symptom measure, the Achalasia Patient‐Reported Outcomes (APRO) QuestionnaireMethodsFour gastroenterologists with achalasia expertise generated preliminary items. Patients reviewed items via cognitive interviews. Patients undergoing high‐resolution manometry completed the APRO with Oesophageal Hypervigilance and Anxiety Scale, Northwestern Oesophageal Quality of Life Scale, and three measures of reflux and dysphagia. Full APRO psychometric assessment (reliability, validity, factor structure) was done. Cluster analysis evaluated APRO + symptom‐anxiety/hypervigilance patient phenotypes.ResultsWe included 961 patients with normal motility and 296 with achalasia. The APRO yielded three subscales: dysphagia, reflux, chest pain with two items for weight change and diet modifications. Reliability and validity were excellent. Twenty‐five percent of achalasia patients may have high levels of anxiety/hypervigilance despite low symptoms, while 8% may report severe symptoms with low anxiety/hypervigilance. The APRO significantly predicted quality of life, but less cognitive‐affective processes.ConclusionsThe APRO is a reliable and valid measure of achalasia symptoms that addresses the limitations of existing questionnaires. Symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life; 33% of patients with achalasia exhibit concerning patterns in symptom severity, anxiety and hypervigilance that may contribute to poorer outcomes.
Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
Oddis, Chester V. , Rockette, Howard E., Zhu, Lei , Koontz, Diane, Lacomis, David , Venturupalli, Swamy, Moghadam‐Kia, Siamak , Ascherman, Dana P. , Dimachkie, Mazen M. , Ernste, Floranne C. , Gazeley, David , Marder, Galina , Ascherman, Dana P. , Oddis, Chester V , Dimachkie, Mazen M , Crofford, Leslie J. , Aggarwal, Rohit

Mayo Clinic

ACR Open Rheumatology | September 21, 2022 | Volume: 4 | Issue: 11 | Pages: 983-990

10.1002/acr2.11493 | PMID 36128663 Get It

Objective To assess the efficacy and tolerability of tocilizumab in a multicenter, randomized, double‐blind, placebo‐controlled trial in refractory adult patients with dermatomyositis (DM) and polymyositis (PM). Methods Thirty‐six subjects with probable or definite DM/PM were enrolled in a 6‐month phase 2B clinical trial and randomized 1:1 to receive tocilizumab (8 mg/kg intravenously) or placebo every 4 weeks for 24 weeks. Eligible subjects had either a DM rash, a myositis‐associated autoantibody or an adjudicated PM diagnosis. Active disease was defined by at least three of six abnormal core set measures (CSMs), including a manual muscle testing (MMT)‐8 score of less than 136/150. If the MMT‐8 score was greater than 136, then a cutaneous score of 3 or more (10 cm visual analogue scale) was required along with three additional abnormal CSMs indicating disease activity. The primary endpoint compared the Total Improvement Score (TIS) between both arms from week 4 to 24. Secondary outcomes included time to meeting minimal TIS improvement, changes in CSMs, time to worsening, steroid‐sparing effect, proportion of subjects meeting more stringent improvement criteria, and safety outcomes. Results There was no significant difference ( P = 0.86) in the TIS over 24 weeks between tocilizumab and placebo arms. The secondary endpoints of time to improvement (minimal, moderate, or major), time to worsening, CSM changes, safety outcomes, and steroid‐sparing effect were also not significantly different between arms. Conclusion Tocilizumab was safe and well tolerated but did not meet the primary or secondary efficacy outcomes in refractory DM and PM in this 24‐week phase 2B study.
Transfer learning identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies
Stivers, Katlin B. , Gray-Gaillard, Elise , Ruta, Anna , Hamada, Naomi, Hamada, Masakazu , Trewartha, Shawn , Wolf, Matthew, Keerthivasan, Shilpa , Saux, Claude Le, Housseau, Franck , Deursen, Jan M. van , Pardoll, Drew, Elisseeff, Jennifer H. , Cherry, Christopher, Andorko, James I. , Krishnan, Kavita , Mejías, Joscelyn C. , Nguyen, Helen Hieu , Han, Jin , Hamada, Naomi, Hamada, Masakazu, Sturmlechner, Ines , Michel, John H. , Huyer, Locke Davenport , Tam, Ada J , Peña, Alexis N. , Fertig, Elana Judith , Baker, Darren J.

Mayo Clinic

No container title available | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1847932/v1 Get It

Abstract Cellular senescence is a state of permanent growth arrest that plays an important role in wound healing, tissue fibrosis, and tumor suppression. Despite senescent cells’ (SnC) pathological role and therapeutic interest, their phenotype in vivo remains poorly defined. Here, we developed an in vivoderived senescence signature using a foreign body response (FBR) fibrosis model in a SnC reporter mouse. We identified pericytes and “cartilage-like” fibroblasts as senescent and defined cell typespecific senescence associated secretory phenotypes (SASP). Transfer learning and senescence scoring identified these two SnC populations along with endothelial and epithelial SnCs in new and publicly available murine and human data single cell RNAseq (scRNAseq) datasets from diverse pathologies. Signaling analysis uncovered crosstalk between SnCs and myeloid cells via an IL34- CSF1R-TGFßR signaling axis, contributing to tissue balance of vascularization and matrix production. Overall, our study provides a senescence signature and a computational approach that may be broadly applied to identify transcriptional profiles and SASP factors produced by SnCs that regulate tissue structure and pathology.
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Fonseca, Rodrigo , Arribas, Mariano , Kusne, Yael , González-Vélez, Miguel , Butterfield, Richard , Stewart, A. Keith , Reeder, Craig B. , Larsen, Jeremy T. , Bergsagel, P. Leif , Bergsagel, P. Leif , Fonseca, Rodrigo , Wiedmeier, Julia E. , Kosiorek, Heidi , Kirsch, Ilan R. , Mıkhael, Joseph , Fonseca, Rafaël

Mayo Clinic

No container title available | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2058259/v1 Get It

Abstract Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in combination with functional imaging remains to be validated. We performed a retrospective analysis on MM patients who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT with NGS MRD and positron emission tomography (PET-CT). Patients with ≥ 2 MRD measurements were included in a secondary analysis for sequential measurements. 186 patients were included in the analysis. At day 100, 45 (24.2%) patients achieved MRD negativity at a sensitivity threshold of 10− 6. MRD negativity was the most predictive factor for longer time to next treatment (TTNT). Negativity rates did not differ according to MM subtype, R-ISS Stage nor cytogenetic risk. PET-CT and MRD positivity had poor agreement. Patients with sustained MRD negativity had longer TTNT, regardless of baseline risk characteristics. Our results show that the “real world” ability to measure deeper and sustainable responses distinguishes a subpopulation of patients with better outcomes. Achieving MRD negativity was the strongest prognostic marker and could help guide therapy-related decisions and serve as a response marker for clinical trials.
Nonalcoholic Fatty Liver Disease (Japanese Version)
Wang, Xiao‐Jing , Malhi, Harmeet

Mayo Clinic

Annals of Internal Medicine | September 20, 2022 | Volume: 169 | Issue: 9 | Pages: JITC65-JITC80

10.7326/istranslatedfrom_aitc201811060_japanese Get It

Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences
Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Bonilla, Hilda Mariana Gonzalez , Acker, Nancy, Murthy, Vishakantha , Shrivastava, Sanskriti , Desai, Viral , Burnett, John C. , Redfield, Margaret M. , Bailey, Kent R. , Weinshilboum, Richard M. , Pereira, Naveen L. , Iyer, Seethalakshmi , Gonzalez Bonilla, Hilda Mariana, Desai, Viral K , Redfield, Margaret, Pereira, Naveen L , Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Weinshilboum, Richard M.

Mayo Clinic

Circulation: Heart Failure | September 20, 2022 | Volume: 15 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.009629 | PMID 35656806 Get It

Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes
Dietrich, Mary S. , Gaitatzis, Katrina , Koelmeyer, Louise , Boyages, John , Abramson, Vandana G. , McLaughlin, Sarah A. , Ngui, Nicholas , French, James , Hsu, Jeremy , Hughes, Michael , Stolldorf, Deonni P. , Shah, Chirag , Ridner, Sheila H. , Ridner, Sheila H , Abramson, Vandana G , Koelmeyer, Louise A , Elder, Elisabeth Edström

Mayo Clinic

Lymphatic Research and Biology | September 20, 2022 | Volume: 21 | Issue: 3 | Pages: 304-313

10.1089/lrb.2022.0020 | PMID 36126315 Get It

Background: Patients underwent a compression (sleeve and gauntlet) intervention for subclinical breast cancer-related lymphedema (S-BCRL). Physical, emotional, and quality-of-life (QoL) outcomes were examined. Associations of change in extracellular fluid alone through bioimpedance spectroscopy (BIS) or change in whole-arm volume through tape measure with the outcomes at time of S-BCRL were explored. Methods and Results: We enrolled newly diagnosed nonmetastatic breast cancer patients for surveillance up to 36 months postoperatively. Upon detection of S-BCRL, a 28-day compression intervention was initiated. Data were obtained through physical examination/measurement and self-report instruments: skin examination, Lymphedema Symptom Intensity and Distress Survey-Arm, and Functional Assessment of Cancer Therapy General (FACT-G), Breast (FACT-B), and FACT-B+4. Improvements with intervention were observed in the proportion of patients reporting symptom scores ≥3 in function (Cohen's d = −0.46, p < 0.01), in biobehavioral (Cohen's d = −0.30, p < 0.05), maximum number of skin conditions (Cohen's d = −0.34, p < 0.05. 3), FACT-B (Cohen's d = 0.52, p < 0.01), and FACT-B + four (Cohen's d = −0.42, p < 0.01). At the study endpoint, compared with those who did not progress, chronic breast cancer-related lymphedema (C-BCRL) progressing patients had higher overall symptom scores ( p = 0.037), more skin conditions ( p = 0.009), and lower total FACT-G and FACT-B scores ( p < 0.05). At the time of S-BCRL, detection of greater BIS unit change correlated with higher symptom, skin condition, and QoL values. Greater whole-arm volume change correlated with higher FACT-B+4 scores (all p < 0.05). Conclusions: Prospective surveillance, symptom assessment, and compression intervention promote low progression rates from S-BCRL to C-BCRL and as such reduce symptom burden. This closed study is registered with ClinicalTrials.gov NCT02167659